Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Fineline Cube Dec 30, 2025
Company Deals

Hansoh Pharma Licenses Hengrui’s SHR6508 for RMB 220 Million to Expand Renal Portfolio

Fineline Cube Dec 29, 2025
Company Deals

Luye Pharma Divests 25% Nanjing Luye Stake in RMB 1.1 Billion Complex Option Deal

Fineline Cube Dec 29, 2025
Company Deals

Transcenta Licenses HiCB Platform to EirGenix for Continuous Biomanufacturing

Fineline Cube Dec 29, 2025
Company Deals

TJ Biopharma Partners with Zhejiang Lab to Develop AI‑Driven Ultra‑Long‑Acting Growth Hormone

Fineline Cube Dec 29, 2025
Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Fineline Cube Dec 30, 2025
Company Drug

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Fineline Cube Dec 30, 2025
Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma

Fineline Cube Dec 30, 2025
Policy / Regulatory

Guangdong Releases 2022 Non-Immunization Vaccine Catalog (7th Batch)

Fineline Cube Jul 5, 2022

The Guangdong Provincial Center for Disease Control and Prevention and Guangdong Medicine Exchange jointly released...

Company

WuXi Biologics’ MFG14 Facility Approved for Microbial Product Manufacturing

Fineline Cube Jul 5, 2022

China-based Contract Research, Development and Manufacturing Organization (CRDMO) WuXi Biologics (HKG: 2269) announced that its...

Company Drug

JW Therapeutics Initiates Phase I Study of JWATM204 for Hepatocellular Carcinoma

Fineline Cube Jul 5, 2022

China-based JW Therapeutics (HKG: 2126) announced the initiation of a Phase I clinical study for...

Company Deals

GenScript Biotech’s ProBio Subsidiary Receives USD 37.25M Investment from Zhenjiang Gaoxin

Fineline Cube Jul 4, 2022

Hong Kong-based Contract Research Organization (CRO) GenScript Biotech Corporation (HKG: 1548) announced that Zhenjiang Gaoxin...

Company Deals

Zhiyi Bio Raises RMB 100M in Series B++ Round for LBP Pipeline Development

Fineline Cube Jul 4, 2022

China-based leading live biotherapeutics (LBP) company Guangzhou Zhiyi Biotechnology Co., Ltd has recently raised RMB...

Company Deals Drug

Brii Biosciences Exercises Option for VIR-3434 in Greater China

Fineline Cube Jul 4, 2022

China-based Brii Biosciences Limited (HKG: 2137) announced the exercise of its option to acquire exclusive...

Company Drug

Innovent Biologics Doses First Patient in IBI112 Phase II Study for Ulcerative Colitis

Fineline Cube Jul 4, 2022

China-based Innovent Biologics, Inc. (HKG: 1801) announced the successful first patient dosing in a Phase...

Company Deals

VivaVision Biotech and Dragon Sail Pharmaceutical Partner on Ophthalmology R & D

Fineline Cube Jul 4, 2022

China’s VivaVision Biotech Inc. has entered into a partnership with compatriot firm Dragon Sail Pharmaceutical....

Company Drug

Junshi Biosciences Receives FDA Approval for PI3K-α Inhibitor RP903 in Breast Cancer Study

Fineline Cube Jul 4, 2022

China’s Junshi Biosciences (HKG: 1877, SHA: 688180) announced that it has received approval from the...

Company Drug

InnoCare Pharma’s Guangzhou Plant Approved for Orelabrutinib Commercial Production

Fineline Cube Jul 4, 2022

Beijing InnoCare Pharma (HKG: 9969) announced that as of June 30, its manufacturing plant in...

Company Drug

Hengrui Medicine’s Generic Tacrolimus Wins NMPA Approval for Transplant Rejection Prevention

Fineline Cube Jul 4, 2022

China-based Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276) announced that it has received market approval...

Company

Medtronic Kanghui and Changzhou High-Tech Zone Partner on Science Park

Fineline Cube Jul 4, 2022

Medtronic Kanghui and Changzhou National High-Tech Industrial Development Zone have agreed to collaborate on the...

Policy / Regulatory

NHC Releases Technical Guidelines for Drug Clinical Evaluation

Fineline Cube Jul 4, 2022

The National Health Commission (NHC) has released the “Technical Guidelines for Comprehensive Clinical Evaluation of...

Company Deals

HitGen and Haichang Bio Partner to Develop Anti-Cancer RNAi Drugs

Fineline Cube Jul 4, 2022

China-based HitGen Inc. (SHA: 688222) announced the establishment of a strategic partnership with compatriot firm...

Policy / Regulatory

Hainan Medical Products Administration Issues Guidelines for Imported Drug Management

Fineline Cube Jul 4, 2022

The Hainan Medical Products Administration (HMPA) has released a set of guidelines that took effect...

Company Drug

Abbisko Therapeutics Doses First Patient in ABSK061 Phase I Study for Solid Tumors

Fineline Cube Jul 4, 2022

Shanghai-based biotech Abbisko Therapeutics Co., Ltd (HKG: 2256) announced the first patient dosing in a...

Company Drug

Ascletis Pharma Doses First Patient in ASC22 HIV Study with Chidamide

Fineline Cube Jul 4, 2022

China-based Ascletis Pharma Inc. (HKG: 1672) announced that the first patient has been dosed in...

Company Deals

Fosun Pharmaceutical and ReNeuron Renew CTX Cell Therapy Deal for China

Fineline Cube Jul 4, 2022

China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) has negotiated a new...

Company

Eurofins DiscoverX Opens Shanghai Office to Expand Asia-Pacific Operations

Fineline Cube Jul 4, 2022

California-based Eurofins DiscoverX Products LLC, a manufacturer of drug discovery solutions, announced the opening of...

Company Deals

Solasia Pharma Reduces China Operations, Transfers Drug Rights to Lee’s

Fineline Cube Jul 4, 2022

Japan-based Solasia Pharma KK (TYO: 4597) announced that it will reduce its direct operations in...

Posts pagination

1 … 591 592 593 … 602

Recent updates

  • HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma
  • Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug
  • Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma
  • Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders
  • Sino Biopharmaceutical’s TDI01 Enrolls First IPF Patient in World’s First ROCK2 Inhibitor Phase III Trial
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

HutchMed’s Fanregratinib Wins NMPA Priority Review for FGFR2+ Cholangiocarcinoma

Company Deals

Buchang Pharmaceuticals Signs Exclusive Malaysia Deal for Efparepoetin CKD Anemia Drug

Company Drug

Easton Pharmaceutical Doses First Patient in Phase I/II Trial of HP‑001 for Relapsed Multiple Myeloma

Policy / Regulatory

Haihe Biopharma’s Risovalisib Enters China SPARK Project for Pediatric PIK3CA Disorders

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.